The Journal of Heart and Lung Transplantation
Volume 27, Issue 7 , Pages 701-709 , July 2008

Increased Expression of Stem Cell Factor and Its Receptor After Left Ventricular Assist Device Support: A Potential Novel Target for Therapeutic Interventions in Heart Failure

  • Jama Jahanyar, MD, PhD

      Affiliations

    • Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, Texas
    • Corresponding Author InformationReprint requests: Jama Jahanyar, MD, PhD, Michael E. DeBakey Department of Surgery, Division of Transplant and Assist Devices, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030. Telephone: 713-790-3155. Fax: 713-797-0613.
    • ,
  • Keith A. Youker, PhD

      Affiliations

    • Methodist DeBakey Heart Center, The Methodist Hospital, Houston, Texas
    • ,
  • Guillermo Torre-Amione, MD, PhD

      Affiliations

    • Methodist DeBakey Heart Center, The Methodist Hospital, Houston, Texas
    • ,
  • Michael M. Koerner, MD, PhD

      Affiliations

    • Department of Medicine, Section of Cardiology, Baylor College of Medicine and Texas Heart Institute, Houston, Texas.
    • ,
  • Brian Bruckner, MD

      Affiliations

    • Methodist DeBakey Heart Center, The Methodist Hospital, Houston, Texas
    • ,
  • George P. Noon, MD

      Affiliations

    • Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, Texas
    • Methodist DeBakey Heart Center, The Methodist Hospital, Houston, Texas
    • ,
  • Matthias Loebe, MD, PhD

      Affiliations

    • Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, Texas
    • Methodist DeBakey Heart Center, The Methodist Hospital, Houston, Texas

Received 6 November 2007 ,Revised 8 February 2008 ,Accepted 27 March 2008.

References 

  1. Brower GL, Janicki JS. Pharmacologic inhibition of mast cell degranulation prevents left ventricular remodeling induced by chronic volume overload in rats. J Card Fail. 2005;11:548–556
  2. Hara M, Ono K, Hwang MW, et al. Evidence for a role of mast cells in the evolution to congestive heart failure. J Exp Med. 2002;195:375–381
  3. Janicki JS, Brower GL, Gardner JD, et al. Cardiac mast cell regulation of matrix metalloproteinase-related ventricular remodeling in chronic pressure or volume overload. Cardiovasc Res. 2006;69:657–665
  4. Matsumoto T, Wada A, Tsutamoto T, et al. Chymase inhibition prevents cardiac fibrosis and improves diastolic dysfunction in the progression of heart failure. Circulation. 2003;107:2555–2558
  5. Palladini G, Tozzi R, Perlini S. Cardiac mast cells in the transition to heart failure: innocent bystanders or key actors?. J Hypertens. 2003;21:1823–1825
  6. Panizo A, Mindan FJ, Galindo MF, et al. Are mast cells involved in hypertensive heart disease?. J Hypertens. 1995;13:1201–1208
  7. Patella V, de Crescenzo G, Lamparter-Schummert B, et al. Increased cardiac mast cell density and mediator release in patients with dilated cardiomyopathy. Inflamm Res. 1997;46(suppl 1):S31–S32
  8. Patella V, Marino I, Arbustini E, et al. Stem cell factor in mast cells and increased mast cell density in idiopathic and ischemic cardiomyopathy. Circulation. 1998;97:971–978
  9. Shiota N, Rysa J, Kovanen PT, et al. A role for cardiac mast cells in the pathogenesis of hypertensive heart disease. J Hypertens. 2003;21:1935–1944
  10. Batlle M, Roig E, Perez-Villa F, et al. Increased expression of the renin–angiotensin system and mast cell density but not of angiotensin-converting enzyme II in late stages of human heart failure. J Heart Lung Transplant. 2006;25:1117–1125
  11. Akgul A, Skrabal CA, Thompson LO, et al. Role of mast cells and their mediators in failing myocardium under mechanical ventricular support. J Heart Lung Transplant. 2004;23:709–715
  12. Akgul A, Youker KA, Noon GP, Loebe M. Quantitative changes in mast cell populations after left ventricular assist device implantation. ASAIO J. 2005;51:275–280
  13. Jahanyar J, Youker KA, Loebe M, et al. Mast cell-derived cathepsin G: a possible role in the adverse remodeling of the failing human heart. J Surg Res. 2007;140:199–203
  14. Skrabal CA, Thompson LO, Southard RE, et al. Interaction between isolated human myocardial mast cells and cultured fibroblasts. J Surg Res. 2004;118:66–70
  15. Meininger CJ, Yano H, Rottapel R, et al. The c-kit receptor ligand functions as a mast cell chemoattractant. Blood. 1992;79:958–963
  16. Mitsui H, Furitsu T, Dvorak AM, et al. Development of human mast cells from umbilical cord blood cells by recombinant human and murine c-kit ligand. Proc Natl Acad Sci USA. 1993;90:735–739
  17. Tsai M, Takeishi T, Thompson H, et al. Induction of mast cell proliferation, maturation, and heparin synthesis by the rat c-kit ligand, stem cell factor. Proc Natl Acad Sci USA. 1991;88:6382–6386
  18. Valent P, Spanblochl E, Sperr WR, et al. Induction of differentiation of human mast cells from bone marrow and peripheral blood mononuclear cells by recombinant human stem cell factor/kit-ligand in long-term culture. Blood. 1992;80:2237–2245
  19. Dastych J, Metcalfe DD. Stem cell factor induces mast cell adhesion to fibronectin. J Immunol. 1994;152:213–219
  20. Iemura A, Tsai M, Ando A, Wershil BK, Galli SJ. The c-kit ligand, stem cell factor, promotes mast cell survival by suppressing apoptosis. Am J Pathol. 1994;144:321–328
  21. Kinashi T, Springer TA. Steel factor and c-kit regulate cell-matrix adhesion. Blood. 1994;83:1033–1038
  22. Mekori YA, Oh CK, Metcalfe DD. IL-3-dependent murine mast cells undergo apoptosis on removal of IL-3 (Prevention of apoptosis by c-kit ligand). J Immunol. 1993;151:3775–3784
  23. Kirshenbaum AS, Kessler SW, Goff JP, Metcalfe DD. Demonstration of the origin of human mast cells from CD34+ bone marrow progenitor cells. J Immunol. 1991;146:1410–1415
  24. Kirshenbaum AS, Goff JP, Semere T, et al. Demonstration that human mast cells arise from a progenitor cell population that is CD34(+), c-kit(+), and expresses aminopeptidase N (CD13). Blood. 1999;94:2333–2342
  25. Jin D, Takai S, Yamada M, et al. Possible roles of cardiac chymase after myocardial infarction in hamster hearts. Jpn J Pharmacol. 2001;86:203–214
  26. Qu Z, Liebler JM, Powers MR, et al. Mast cells are a major source of basic fibroblast growth factor in chronic inflammation and cutaneous hemangioma. Am J Pathol. 1995;147:564–573
  27. Galli SJ. New concepts about the mast cell. N Engl J Med. 1993;328:257–265
  28. Da Silva CA, Reber L, Frossard N. Stem cell factor expression, mast cells and inflammation in asthma. Fundam Clin Pharmacol. 2006;20:21–39
  29. Nilsson G, Butterfield JH, Nilsson K, Siegbahn A. Stem cell factor is a chemotactic factor for human mast cells. J Immunol. 1994;153:3717–3723
  30. Echtenacher B, Mannel DN, Hultner L. Critical protective role of mast cells in a model of acute septic peritonitis. Nature. 1996;381:75–77
  31. Maurer M, Echtenacher B, Hultner L, et al. The c-kit ligand, stem cell factor, can enhance innate immunity through effects on mast cells. J Exp Med. 1998;188:2343–2348
  32. Lorentz A, Schuppan D, Gebert A, Manns MP, Bischoff SC. Regulatory effects of stem cell factor and interleukin-4 on adhesion of human mast cells to extracellular matrix proteins. Blood. 2002;99:966–972
  33. Frangogiannis NG, Perrard JL, Mendoza LH, et al. Stem cell factor induction is associated with mast cell accumulation after canine myocardial ischemia and reperfusion. Circulation. 1998;98:687–698
  34. Matsuzawa S, Sakashita K, Kinoshita T, et al. IL-9 enhances the growth of human mast cell progenitors under stimulation with stem cell factor. J Immunol. 2003;170:3461–3467
  35. Wright HV, Bailey D, Kashyap M, et al. IL-3-mediated TNF production is necessary for mast cell development. J Immunol. 2006;176:2114–2121

 Supported by the George P. Noon Research Fund and the Michael E. DeBakey Foundation.

PII: S1053-2498(08)00283-0

doi: 10.1016/j.healun.2008.03.021

The Journal of Heart and Lung Transplantation
Volume 27, Issue 7 , Pages 701-709 , July 2008

Article Tools

* Image Usage & Resolution